The Leibniz Health Technologies (LGT) research network will be presenting itself at the medical technology trade fair "MT-Connect" in Nuremberg from 21 to 22 June. In Hall 10.0, Stand 304, the Leibniz Research Alliance will join forces with neoplas tools to present the kINPen Med, a compact device that enables the direct treatment of chronic, infected wounds and inflammatory skin diseases using cold plasma. Leibniz Health Technologies will also be presenting the latest approaches to speckle photometry in skin diagnostics and a miniaturised fibre probe for endoscopic applications.
At the medical technology trade fair "MT-Connect" in Nuremberg on 21 and 22 June, "Leibniz Health Technologies" will present the first concrete health technology solutions from its interdisciplinary research.
Together with the Greifswald-based company neoplas tools, Leibniz Health Technologies will present kINPen MED, a particularly innovative technology for plasma medicine applications. This high-tech device resembles a pen and generates what is known as cold plasma – an ionised gas that enables particularly tissue-friendly and painless decontamination and promotes healing in wounds and skin infections.
"Since plasma works primarily through purely physical mechanisms, typical problem germs can be killed very effectively without the development of resistance. At the same time, the plasma stimulates the body's own healing processes, which can thus be restarted even in chronic wounds such as 'open legs'," explains Renate Schönebeck, managing director of neoplas tools. The Greifswald-based company is a spin-off from the Leibniz Institute for Plasma Science and Technology (INP), a member of Leibniz Health Technologies.
The Leibniz Research Alliance will also present new technologies from its fields of expertise in "point-of-care diagnostics" and "imaging methods." For example, the alliance will showcase an on-site diagnostic system based on speckle photometry that enables rapid skin characterisation and early detection of skin cancer. In addition, a new miniaturised fibre probe will be presented, which provides a cost-effective and compact solution for multimodal endoscopic imaging.
"For the signal transmission of the new probe, we use a special multi-core fibre consisting of thousands of light-conducting elements. This allows us to accommodate all moving parts and the power supply outside the probe head. The probe is therefore only a few millimetres in size and can be used easily and safely inside the body," explains Prof. Jürgen Popp, Scientific Director of the Leibniz Institute for Photonic Technologies Jena (Leibniz IPHT) and Director of the Institute of Physical Chemistry at Friedrich Schiller University Jena. The Leibniz IPHT coordinates the research network and is leading the further development of both multimodal fibre-optic imaging and speckle photometry.
The MT-Connect medical technology trade fair connects suppliers with specialists in medicine, electronics and IT, optoelectronics and minimally invasive technologies, diagnostics, sales and marketing. In addition, the MedTech Summit, held parallel to the trade fair, is an internationally oriented forum dedicated to the future topics of the industry.
Leibniz Health Technologies will be exhibiting at MT-Connect (Hall 10.0, Stand 304) to showcase its technologies. An electronic admission voucher (e-code) for a free trade fair ticket can be requested by emailing info@leibniz-healthtech.de.
_________________________________________
Leibniz Health Technologies is a research network of the Leibniz Association. Within this network, 14 member institutes work on concrete technological solutions to pressing medical issues and pursue the common goal of improving medical care for patients. Through an interdisciplinary approach, prevention, diagnostics and therapy are to be integrated, thereby improving quality of life.
The Leibniz Research Alliance combines expertise from a wide range of scientific fields, ranging from photonics and medicine to microelectronics and materials research to business research and applied mathematics. This results in health technologies that are brought to market maturity in collaboration with industry, clinics, insurance companies and politics along a seamless innovation chain. In parallel, Leibniz Health Technologies researches the social and economic consequences of new medical technologies in order to optimise their benefits for users and create broad social acceptance for new technologies.
